Mechanisms studied to date suggest that NAFLD may increase the risk of developing T2DM by exacerbating hepatic insulin resistance, leading to the release of inflammatory mediators and diabetic hepatokines such as fetuin-A/B and fibroblast growth factor 21 (FGF21) [26]. This evidence concerns the gene AHSG and metabolic dysfunction-associated steatotic liver disease.